Takeda to Differentiate New ARB Azilva Stressing Its Strong Hypotensive Effects

Naoyuki Suzuki, Vice President, Ethical Products Marketing Department, Pharmaceutical Marketing Division Takeda Pharmaceutical intends to fully promote the hypotensive effects of its new angiotensin II receptor blocker (ARB) Azilva (azilsartan), expected to be launched in late May, in order to...read more